64th ASH Annual Meeting and Exposition: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutics

Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Biological therapies, AML, apoptosis, adult, Translational Research, CLL, Lymphomas, non-Hodgkin lymphoma, LGL, B Cell lymphoma, Plasma Cell Disorders, genomics, Combination therapy, T Cell lymphoma, drug development, Diseases, indolent lymphoma, drug-drug interactions, aggressive lymphoma, Therapies, Lymphoid Malignancies, Adverse Events, Biological Processes, Monoclonal Antibody Therapy, molecular biology, Study Population, Human, Animal model

391-392 (Ernest N. Morial Convention Center)

Moderators:

Joanna S. Yi, MD, Texas Children's Hospital and Jennifer E. Amengual, MD,

Disclosures:

Amengual: Daiichi Sankyo: Consultancy; AstraZeneca: Consultancy; Appia Pharmaceuticals: Research Funding.

4:30 PM

937

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Bimarzhan Assatova^1,2^*, Christopher Trevisani^1,3^*, Robert Willim, MD^4,5^*, Jessica Duffy⁶^*, Abner Louissaint Jr., MD, PhD^7,8, Won-Seog Kim, MD, PhD⁹^*, David J Feith, PhD¹⁰^*, Thomas Loughran Jr.¹¹^*, Foster Powers^1,12^*, Elizabeth A Morgan, MD^7,13, Lei Yang^1,14^*, Brandy Pinckney¹⁵^*, Garrett Haskett¹⁵^*, Matthew J Cotton¹⁵^*, Andrew Crabbe^6,16^*, Jessica Beth Ziemba, MD^4,17^*, Ian Brain^13,18^*, Tayla B. Heavican-Foral, PhD¹⁹, Nora Scanlan⁶^*, Gail Newton⁶^*, Jaehyuk Choi, MD PhD²⁰, Jeffrey A Barnes, MD, PhD^7,21, Patrick Connor Johnson, MD^5,21, Eric D Jacobsen, MD^1,7^*, Steven Greenberg^7,22^*, David M. Weinstock, MD^1,7,23,24 and Salvia Jain, MD^7,21,25

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Medicine, Massachusetts General Hospital Cancer Center, Brookline, MA
³College of Medicine, SUNY Upstate Medical University, Syracuse, NY
⁴Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA
⁵Harvard Medical School, Boston
⁶Department of Pathology, Massachusetts General Hospital, Boston, MA
⁷Harvard Medical School, Boston, MA
⁸Massachusetts General Hospital, Boston, MA
⁹Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
¹⁰University of Virginia Cancer Center, University of Virginia, Charlottesville, VA
¹¹Division of Hematology/Oncology, Department of Medicine, UVA Cancer Center, University of Virginia, Charlottesville
¹²Department of Medicine, University of Minnesota, Minneapolis, MN
¹³Department of Pathology, Brigham and Women’s Hospital, Boston, MA
¹⁴Graduate School of Biological Sciences, University of Texas, MD Anderson Cancer Center, Houston
¹⁵Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
¹⁶Department of Pathology, Akron General, Cleveland Clinic, Akron, OH
¹⁷Histopath, Inc, Corpus Christi
¹⁸Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
¹⁹Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
²⁰Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL
²¹Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA
²²Department of Neurology, Brigham and Women’s Hospital, Boston
²³Broad Institute of MIT and Harvard, Cambridge, MA
²⁴Merck Research Labs, Boston
²⁵Broad Institute of Harvard and MIT, Cambridge, MA

4:45 PM

938

Therapeutic Repurposing of Brincidofovir in Natural Killer/T-Cell Lymphoma Reveals Potent Induction of Replication Stress, Sting Pathway Activation and Immunogenic Cell Death

Jason Yongsheng Chan, MBBS, PhD^1,2,3, Elizabeth Chun Yong Lee, BS³^*, Kelila Xin Ye Chai, MS⁴^*, Jing Yi Lee, BS³^*, Bavani Kannan, BS³^*, Boon Yee Lim, BS³^*, Jessica Sook-Ting Kok, BS⁵^*, Zhimei Li, MS³^*, Jui Wan Loh, PhD³^*, Tun Kiat Ko, PhD³^*, Kah Suan Lim, PhD⁵^*, Cedric Chuan-Young Ng, MS³^*, Kerry Lim, BS⁴^*, Dachuan Huang, PhD⁴, Jing Quan Lim, PhD⁴^*, Masatoshi Hazama, PhD⁶^*, Koji Fukushima, MD, PhD⁶^*, Bin Tean Teh, MD, PhD^2,5,7^*, Soon Thye Lim, MBBS^1,8^* and Choon Kiat Ong, PhD^2,4,7

¹Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
²Duke-NUS Medical School, Singapore, Singapore
³Cancer Discovery Hub, National Cancer Centre Singapore, Singapore, Singapore
⁴Lymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore
⁵Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore
⁶SymBio Pharmaceuticals Limited, Minato-Ku, TKY, Japan
⁷Genome Institute of Singapore, Singapore, Singapore
⁸Office of Education, Duke-NUS Medical School, Singapore, Singapore

5:00 PM

939

Choline Kinase a Is Required for Alkylating Agent Resistance in T-Cell Acute Lymphoblastic Leukemia

Anais Barthe¹^*, Kimberly Bodaar, MD¹, Aaron Issaian, PhD²^*, Eric Aboagye³^*, Angelo D'Alessandro, PhD² and Alejandro Gutierrez, MD^1,4

¹Department of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
²Department of Biochemistry and Molecular Genetics, School of Medicine-Anschutz Medical Campus, University of Colorado, Aurora, CO
³Department of surgery and Cancer, Imperial college London, London, United Kingdom
⁴Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA

5:15 PM

940

DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Kelly Shi, PhD¹^*, Cindy Tan²^*, Lu Bai²^*, Jennifer Richardson, PhD, DABT²^*, Andy Deng, PhD²^*, Matthias Will, MD², Michael Brehm, PhD³^*, Dale Greiner, PhD⁴^*, Leonard Shultz, PhD⁵^*, Antonella Teramo, PhD⁶^*, Renato Zambello, MD⁷^*, David J Feith, PhD⁸^*, Thomas P. Loughran Jr., MD⁹ and Nenad Tomasevic, PhD²^*

¹Dren Bio, Inc., San Carlos, CA
²Dren Bio, Inc., Foster City
³University of Massachusetts Medical School, Worcester, MA
⁴UMass Med. School, Worcester, MA
⁵The Jackson Laboratory, Bar Harbor, ME
⁶Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy
⁷Veneto Institute of Molecular Medicine (VIMM), Padova, Italy
⁸University of Virginia Cancer Center, University of Virginia, Charlottesville, VA
⁹Division of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, VA

5:30 PM

941

The Cyclin-G Associated Kinase (GAK) Is a Critical Dependency for Cell-Cycle Progression in Diffuse Large B-Cell Lymphoma Associated with Deregulation of the Retinoblastoma Tumor Suppressor

Austin D. Newsam, BS¹^*, Preet Kumar, BS¹^*, Olivia B. Lightfuss¹^*, Lingxiao Li, PhD²^*, Anirban Ghoshal, PhD³^*, Stephan Schürer, Ph.D⁴^*, Vance Lemmon, PhD⁵^*, Yangbo Feng, PhD³^*, Hassan Al-Ali, PhD, MSc⁶^* and Jonathan H. Schatz, MD^2,7,8

¹Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
²Sylvester Comprehensive Cancer Center, Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL
³University of Miami Miller School of Medicine, Miami, FL
⁴Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL
⁵University of Miami, Miami
⁶Department of Neurological Surgery, Department of Medicine, University of Miami, Miami, FL
⁷Department of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
⁸Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL

5:45 PM

942

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

Shanshan Suo, MD^1,2^*, Shu SUN²^*, Jiejing Qian, MD, PhD²^*, Dandan Zhao, MD¹^*, Wenjuan Yu, MD, PhD²^*, Yinjun Lou, MD, PhD²^*, Honghu Zhu, MD²^*, Hongyan Tong, MD, PhD²^*, Min Yang, M.D.²^*, Xin Huang, Ph.D.²^*, Shuqi Zhao²^*, Junjing Qiao, MD, PhD¹^*, Chen Liang, MD¹^*, Fenglin Li²^*, Huafeng Wang²^*, Yi Zhang, M.D.²^*, Le Xuan Truong Nguyen, PhD¹^*, Dinh Hoa Hoang, BS¹^*, Fang Chen¹^*, Jie Sun, PhD²^*, Ivan Rodriguez¹^*, Lucy Ghoda, PhD²^*, Ling Li, PhD¹, Bin Zhang, PhD¹, Guido Marcucci, MD¹ and Jie Jin, M.D., Ph.D.²

¹Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Duarte, CA
²Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.O3.6 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutics